NEWS & VIEWS

Global private equity and venture capital news and research

Posts Tagged ‘biopharmaceutical’

19 May 2014

US biopharma Proteon Therapeutics raises $45m Series D

US biopharmaceutical company Proteon Therapeutics has closed a $45m of Series D equity financing, including a $25m tranche to fully fund the first Phase 3 clinical study of its lead product.

16 April 2014

Biopharma developer PanOptica scores $45m Series B investment

Biopharmaceutical company PanOptica has raised up to $45m in a Series B financing, co-led by new participant Novo Ventures and existing investor Third Rock Ventures, alongside founding investor SV Life Sciences.

1 April 2014

Investors exit biopharma services company Aptiv in $144m sale

Investors including the Halifax Group, SV Life Sciences and Comvest Partners have exited their stake in biopharmaceutical and medical device development services company Aptiv Solutions to ICON for $143.5m.

28 March 2014

Biopharma developer scPharmaceuticals seals $16m Series A VC round

Biopharmaceutical company scPharmaceuticals has closed a $16m Series A venture financing round co-led by life sciences investors 5AM Ventures and Lundbeckfond Ventures.

24 March 2014

Venture capital-backed Versartis soars after IPO

Venture capital-backed Versartis soars after IPO

12 February 2014

VC backed Cadence Pharmaceuticals sells for $1.3bn

NYSE-listed pharmaceuticals company Mallinckrodt has agreed to acquire VC-backed Cadence Pharmaceuticals for $1.3bn.

6 February 2014

VC-backed biopharma Circassia eyes London IPO

Venture capital-backed biopharmaceutical company Circassia has confirmed plans to float on the London Stock Exchange’s Main Market.

21 January 2014

French biopharma developer Synthelis secures seed investment

French biopharmaceutical developer Synthelis has secured initial backing of €610,000 from investors comprising Rhone-Alpes Creation, Alpes Developpement Durable Investissement (A2D-Invest), Sud Rhone-Alpes Capital, Viaduc and the Savoy and Grenoble Business Angels networks.

20 November 2013

Sofinnova exits Ethical Oncology Science in $420m deal

biotech_lrg Sofinnova Partners has exited its investment in Italian biopharmaceutical startup Ethical Oncology Science to Clovis Oncology for up to $420m.

11 November 2013

VC-backed GlycoMimetics postpones $64m-targeting IPO

Venture capital-backed biotech company GlycoMimetics has reportedly postponed its IPO, which was supposed to launch last Friday targeting up to $64m.

Page 1 of 512345

Legals & Terms of UsePrivacy Policy


AltAssets is registered as a trademark of Investor Networks Limited (06695690).
Registered Office: Zetland House, 5-25 Scrutton St, London EC2A 4HJ
Content is © AltAssets 2000-2014